Stephen Xu

2.5k total citations
61 papers, 1.7k citations indexed

About

Stephen Xu is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Stephen Xu has authored 61 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Rheumatology, 26 papers in Hematology and 18 papers in Immunology. Recurrent topics in Stephen Xu's work include Rheumatoid Arthritis Research and Therapies (38 papers), Spondyloarthritis Studies and Treatments (26 papers) and Autoimmune and Inflammatory Disorders Research (26 papers). Stephen Xu is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (38 papers), Spondyloarthritis Studies and Treatments (26 papers) and Autoimmune and Inflammatory Disorders Research (26 papers). Stephen Xu collaborates with scholars based in United States, Canada and Germany. Stephen Xu's co-authors include Benjamin Hsu, Désirée van der Heijde, Jürgen Braun, Elizabeth C. Hsia, Robert D. Inman, E. William St. Clair, Daniel Aletaha, Josef S Smolen, Atul Deodhar and Yiying Zhou and has published in prestigious journals such as Gastroenterology, International Journal of Molecular Sciences and Annals of the Rheumatic Diseases.

In The Last Decade

Stephen Xu

60 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen Xu United States	25	1.2k	657	543	246	179	61	1.7k
John Han United States	17	1.9k 1.5×	754 1.1×	831 1.5×	127 0.5×	261 1.5×	20	2.3k
Masao Nawata Japan	24	1.2k 1.0×	536 0.8×	344 0.6×	214 0.9×	316 1.8×	47	1.8k
Hemlata Varsani United Kingdom	20	571 0.5×	891 1.4×	417 0.8×	607 2.5×	106 0.6×	31	1.7k
Tanja Kveder Slovenia	23	1.1k 0.9×	375 0.6×	523 1.0×	160 0.7×	31 0.2×	63	1.7k
Kalliopi Fragiadaki Greece	18	686 0.6×	437 0.7×	160 0.3×	103 0.4×	121 0.7×	26	1.4k
Mathias Grünke Germany	19	674 0.5×	642 1.0×	221 0.4×	99 0.4×	63 0.4×	41	1.4k
Hiroto Tsuboi Japan	23	903 0.7×	580 0.9×	202 0.4×	355 1.4×	59 0.3×	134	1.9k
H. Kellner Germany	15	1.9k 1.5×	825 1.3×	762 1.4×	144 0.6×	34 0.2×	52	2.3k
R. H. W. M. Derksen Netherlands	25	1.3k 1.1×	619 0.9×	544 1.0×	69 0.3×	86 0.5×	41	1.9k
Mittermayer B. Santiago Brazil	20	1.3k 1.0×	659 1.0×	108 0.2×	166 0.7×	57 0.3×	65	1.8k

Countries citing papers authored by Stephen Xu

Since Specialization

Citations

This map shows the geographic impact of Stephen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Xu more than expected).

Fields of papers citing papers by Stephen Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Xu. The network helps show where Stephen Xu may publish in the future.

Co-authorship network of co-authors of Stephen Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Xu. A scholar is included among the top collaborators of Stephen Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Xu. Stephen Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McGonagle, Dennis, Iain B. McInnes, Atul Deodhar, et al.. (2023). Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR Open Rheumatology. 5(4). 227–240. 4 indexed citations

Mease, Philip J., Dafna D. Gladman, Denis Poddubnyy, et al.. (2023). Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study. Rheumatology and Therapy. 10(6). 1637–1653. 11 indexed citations

Schechtman, Joy, Alan Kivitz, Natalie J. Shiff, et al.. (2023). Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study. BMC Rheumatology. 7(1). 5–5. 1 indexed citations

Ritchlin, Christopher T., Philip J. Mease, Wolf‐Henning Boehncke, et al.. (2022). Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open. 8(1). e002195–e002195. 18 indexed citations

Coates, Laura C., Christopher T. Ritchlin, Laure Gossec, et al.. (2022). Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Lara D. Veeken. 62(2). 606–616. 11 indexed citations

Gladman, Dafna D., Philip J. Mease, Paul Bird, et al.. (2022). Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 23(1). 743–743. 34 indexed citations

Deodhar, Atul, Soumya D. Chakravarty, Natalie J. Shiff, et al.. (2022). Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis. JCR Journal of Clinical Rheumatology. 28(8). 420–423. 1 indexed citations

Reveille, John D., Atul Deodhar, Akgun Ince, et al.. (2020). Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial. Value in Health. 23(10). 1281–1285. 6 indexed citations

Mease, Philip J., M. Elaine Husni, Shelly Kafka, et al.. (2020). Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. Arthritis Research & Therapy. 22(1). 43–43. 6 indexed citations

10.

Braun, Jürgen, Xenofon Baraliakos, Kay‐Geert Hermann, Stephen Xu, & Benjamin Hsu. (2016). Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab. The Journal of Rheumatology. 43(5). 901–906. 12 indexed citations

11.

Keystone, Edward, Mark C. Genovese, Stephen Hall, et al.. (2015). Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. The Journal of Rheumatology. 43(2). 298–306. 35 indexed citations

12.

Deodhar, Atul, Jürgen Braun, Robert D. Inman, et al.. (2014). Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Annals of the Rheumatic Diseases. 74(4). 757–761. 101 indexed citations

13.

Fürst, Daniel E., Jonathan Kay, Mary Chester Wasko, et al.. (2013). The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Lara D. Veeken. 52(10). 1845–1855. 26 indexed citations

14.

Keystone, Edward, Mark C. Genovese, Stephen Hall, et al.. (2013). Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension. The Journal of Rheumatology. 40(7). 1097–1103. 33 indexed citations

15.

Braun, Jürgen, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2013). The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Annals of the Rheumatic Diseases. 73(6). 1107–1113. 98 indexed citations

16.

Braun, Jürgen, Atul Deodhar, Robert D. Inman, et al.. (2011). Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Annals of the Rheumatic Diseases. 71(5). 661–667. 82 indexed citations

17.

Braun, Jürgen, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2011). Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Annals of the Rheumatic Diseases. 71(6). 878–884. 72 indexed citations

18.

Braun, Jürgen, Désirée van der Heijde, Mittie K. Doyle, et al.. (2009). Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Care & Research. 61(8). 1032–1036. 27 indexed citations

19.

Rich, Phoebe, C.E.M. Griffiths, Kristian Reich, et al.. (2007). Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Journal of the American Academy of Dermatology. 58(2). 224–231. 121 indexed citations

20.

Cohn, Robert, Stephen Xu, H. G. Wagner, Ferenc Joó, & I. Klatzo. (1992). Decreased visual evoked cortical response latency associated with cerebral ischaemia in the gerbil. Neurological Research. 14(3). 248–251. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact